查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1889482

2025年全球人源化抗体市场报告

Humanized Antibody Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，人源化抗体市场发展迅速，预计将从2024年的357亿美元成长到2025年的397亿美元，复合年增长率达13.2%。过去几年的成长可归因于对标靶治疗的需求不断增长、慢性病患病率上升、单株抗体的应用日益广泛、生物相似药市场不断扩大以及医疗费用支出不断增长。

预计未来几年人源化抗体市场将快速成长，到2029年市场规模将达到643.3亿美元，复合年增长率（CAGR）为12.8%。预测期内的成长可归因于癌症发生率上升、自体免疫疾病盛行率增加、个人化医疗需求成长、生物相似药市场扩张以及医疗费用支出增加。预测期内的关键趋势包括：利用人工智慧（AI）和机器学习进行抗体发现、利用冷冻电子显微镜进行结构测定、利用新一代定序技术进行抗体库分析、利用单细胞核糖核酸（RNA）定序进行标靶检验，以及采用优化连接子和有效载荷的抗体药物偶联物（ADC）。

预计未来几年，感染疾病的日益普及将推动人源化抗体市场的成长。感染疾病是由病原微生物（例如细菌、病毒、真菌和寄生虫）引起的疾病，可透过直接或间接途径在人与人之间传播。随着旅行的增加，病原体的跨境传播速度加快，感染疾病率也上升。人源化抗体透过提供标靶免疫反应来辅助感染疾病治疗，非常适合对抗特定病原体。它们与天然人类抗体高度相似，降低了免疫排斥的风险，从而提高了治疗的安全性和有效性。例如，根据英国政府机构英国卫生安全局的数据，截至2024年2月，英格兰的结核病病例数在2023年达到4,850例，比2022年的4,380例增加了10.7% 。感染疾病的日益普及正在推动人源化抗体市场的成长。

人源化抗体市场的主要企业正在开发创新产品，例如人源化双特异性抗体，以拓展适应症并提供更强效、更持久的抗肿瘤活性。人源化双特异性抗体旨在同时结合两种不同的抗原或同一抗原上的两个不同表位，并经过基因工程改造，使其结构与天然人源抗体高度相似。例如，2024年11月20日，总部位于爱尔兰的生物製药公司Jazz Pharmaceuticals的Ziihera（zanidatamab-hrii）获得美国食品药物管理局（FDA）的加速批准，用于治疗先前接受过核准的不可切除或转移性HER2阳性（IHC 3+）胆道癌。这种人源化免疫球蛋白G（IgG）双特异性抗体标靶人类表皮生长因子受体2（HER2）的两个细胞外位点。其独特的作用机制能够募集免疫效应细胞并直接诱导癌细胞凋亡，从而无需预先激活免疫反应即可靶向攻击恶性细胞。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球人源化抗体：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球人源化抗体市场：成长率分析
  • 全球人源化抗体市场表现：规模与成长，2019-2024年
  • 全球人源化抗体市场预测：规模与成长，2024-2029年，2034年
  • 全球人源化抗体：潜在市场规模 (TAM)

第六章 市场细分

  • 全球人源化抗体市场（依抗体类型划分）：效能及预测，2019-2024年、2024-2029年、2034年
  • 人源化抗体
  • 嵌合体抗体
  • 全人源化抗体
  • 小鼠抗体
  • 全球人源化抗体市场依产品类型、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 单株抗体
  • 多株抗体
  • 抗体药物偶联物
  • 全球人源化抗体市场依应用、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 癌症
  • 自体免疫疾病
  • 感染疾病
  • 心血管疾病
  • 其他的
  • 全球人源化抗体市场依最终用户、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 医院
  • 研究所
  • 诊断实验室
  • 其他的
  • 全球人源化抗体市场：人源化抗体细分市场，按类型、性能和预测（2019-2024年、2024-2029年、2034年）
  • 单特异性治疗抗体
  • 双特异性和多特异性抗体
  • 抗体药物偶联物
  • 基于单链可变片段的抗体
  • 基于片段抗原结合的抗体
  • 全球人源化抗体市场：嵌合体抗体细分市场，按类型、性能和预测（2019-2024年、2024-2029年、2034年）
  • 单特异性治疗抗体
  • 双特异性和多特异性抗体
  • 抗体药物偶联物
  • 基于单链可变片段的抗体
  • 基于片段抗原结合的抗体
  • 全球人源化抗体市场：全人源化抗体细分市场，按类型、性能和预测（2019-2024年、2024-2029年、2034年）
  • 单特异性治疗抗体
  • 双特异性和多特异性抗体
  • 抗体药物偶联物
  • 基于单链可变片段的抗体
  • 延长半衰期抗体
  • 全球人源化抗体市场：小鼠抗体细分市场，按类型、性能和预测，2019-2024年、2024-2029年、2034年
  • 单一特异性研究级抗体
  • 融合瘤衍生抗体
  • 抗体-药物偶联物前驱
  • 基于单链可变片段的抗体
  • 基于片段抗原结合的抗体

第七章 区域和国家分析

  • 全球人源化抗体市场：依地区、绩效及预测划分，2019-2024年、2024-2029年、2034年
  • 全球人源化抗体市场：依国家、表现及预测划分，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 人源化抗体市场：竞争格局
  • 人源化抗体市场：公司概况
    • Johnson & Johnson
    • Roche Holding AG
    • Merck & Co. Inc.
    • Pfizer Inc.
    • AbbVie Inc.

第31章：其他领先和创新企业

  • Sanofi SA
  • Novartis AG
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Biogen Inc.
  • Daiichi Sankyo Company Limited
  • UCB SA
  • Genmab A/S
  • Xencor Inc.
  • Zymeworks Inc.
  • MacroGenics Inc.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第三十五章：具有高市场潜力的国家及其策略

  • 2029年人源化抗体市场：提供新机会的国家
  • 2029年人源化抗体市场：新兴细分市场机会
  • 2029年人源化抗体市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r40030

Humanized antibody is a type of monoclonal antibody engineered to closely mimic human antibodies while maintaining the antigen binding specificity of the original non human antibody. It is produced by replacing most of the non human antibody's protein sequences with corresponding human sequences, reducing the risk of immune reactions. It is widely used in research and therapy to target specific molecules with high precision and lower immunogenicity.

The main antibody types of humanized antibodies include humanized antibodies, chimeric antibodies, fully human antibodies, and murine antibodies. Humanized antibodies are laboratory engineered antibodies originally derived from non human species in which most of the molecular structure is replaced with human antibody components while retaining only the antigen binding regions necessary for target recognition. The various product types include monoclonal antibodies, polyclonal antibodies, and antibody drug conjugates, and they are applied in cancer, autoimmune diseases, infectious diseases, cardiovascular diseases, and others, serving end users such as hospitals, research institutes, diagnostic laboratories, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The humanized antibody market research report is one of a series of new reports from The Business Research Company that provides humanized antibody market statistics, including humanized antibody industry global market size, regional shares, competitors with a humanized antibody market share, detailed humanized antibody market segments, market trends and opportunities, and any further data you may need to thrive in the humanized antibody industry. This humanized antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The humanized antibody market size has grown rapidly in recent years. It will grow from $35.70 billion in 2024 to $39.70 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to rising demand for targeted therapies, increasing prevalence of chronic diseases, growing adoption of monoclonal antibodies, expansion of the biosimilar market, and rising healthcare expenditure.

The humanized antibody market size is expected to see rapid growth in the next few years. It will grow to $64.33 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising incidence of cancer, increasing prevalence of autoimmune diseases, growing demand for personalized medicine, expansion of the biosimilar market, and rising healthcare expenditure. Major trends in the forecast period include artificial intelligence and machine learning driven antibody discovery, cryo-electron microscopy enabled structure determination, next generation sequencing powered repertoire mining, single cell ribonucleic acid sequencing for target validation, and antibody drug conjugates with optimized linkers and payloads.

The growing prevalence of infectious diseases is expected to drive the growth of the humanized antibody market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The incidence of infectious diseases is rising due to increased travel, which accelerates the spread of pathogens across borders. Humanized antibodies support infectious disease treatment by providing targeted immune responses, making them suitable for combating specific pathogens. They reduce the risk of immune rejection by closely resembling natural human antibodies, improving treatment safety and therapeutic effectiveness. For example, in February 2024, according to the UK Health Security Agency, a UK based government agency, tuberculosis cases in England rose to 4,850 in 2023, an increase of 10.7 percent from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the expansion of the humanized antibody market.

Major companies in the humanized antibody market are developing innovative products such as humanized bispecific antibodies to expand labelable indications and provide stronger, more durable antitumor activity. Humanized bispecific antibodies are engineered to bind simultaneously to two different antigens or two distinct epitopes on the same antigen while being modified to closely resemble natural human antibodies. For example, on November 20, 2024, Jazz Pharmaceuticals plc, an Ireland based biopharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration for Ziihera (zanidatamab-hrii) for previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is a humanized, immunoglobulin G bispecific antibody targeting human epidermal growth factor receptor 2 (HER2) at two extracellular sites. It incorporates a proprietary mechanism that engages immune effector cells and directly induces apoptosis in cancer cells, enabling a targeted attack on malignant cells without prior immune activation.

In September 2024, Valerio Therapeutics S.A., a France based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. Through this acquisition, Valerio Therapeutics aims to strengthen its antibody discovery capabilities by integrating Emglev's humanized single-domain antibody (sdAb) technology to accelerate the development of next-generation therapeutic candidates across multiple disease areas. Emglev Therapeutics is a France based biotechnology company specializing in humanized single-domain antibody development.

Major companies operating in the humanized antibody market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, Xencor Inc., Zymeworks Inc., MacroGenics Inc.

North America was the largest region in the humanized antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in humanized antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the humanized antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The humanized antibody market consists of sales of humanized bispecific antibodies, humanized antibody fragments, humanized antibody libraries, and antibody humanization kits and reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Humanized Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on humanized antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for humanized antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The humanized antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Antibody Type: Humanized Antibodies; Chimeric Antibodies; Fully Human Antibodies; Murine Antibodies
  • 2) By Product Type: Monoclonal Antibodies; Polyclonal Antibodies; Antibody-Drug Conjugates
  • 3) By Application: Cancer; Autoimmune Diseases; Infectious Diseases; Cardiovascular Diseases; Other Applications
  • 4) By End-User: Hospitals; Research Institutes; Diagnostic Laboratories; Other End-Users
  • Subsegments:
  • 1) By Humanized Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
  • 2) By Chimeric Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
  • 3) By Fully Human Antibodies: Monospecific Therapeutic Antibodies; Bispecific And Multispecific Antibodies; Antibody Drug Conjugates; Single Chain Variable Fragment Based Antibodies; Long Acting Half Life Extended Antibodies
  • 4) By Murine Antibodies: Monospecific Research Grade Antibodies; Hybridoma Derived Antibodies; Antibody Drug Conjugate Precursors; Single Chain Variable Fragment Based Antibodies; Fragment Antigen Binding Based Antibodies
  • Companies Mentioned: Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca PLC; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; Biogen Inc.; Daiichi Sankyo Company Limited; UCB S.A.; Genmab A/S; Xencor Inc.; Zymeworks Inc.; MacroGenics Inc.
  • Countries:

Table of Contents

1. Executive Summary

2. Humanized Antibody Market Characteristics

3. Humanized Antibody Market Trends And Strategies

4. Humanized Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Humanized Antibody Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Humanized Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Humanized Antibody Market Growth Rate Analysis
  • 5.4. Global Humanized Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Humanized Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Humanized Antibody Total Addressable Market (TAM)

6. Humanized Antibody Market Segmentation

  • 6.1. Global Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Humanized Antibodies
  • Chimeric Antibodies
  • Fully Human Antibodies
  • Murine Antibodies
  • 6.2. Global Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody-Drug Conjugates
  • 6.3. Global Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Other Applications
  • 6.4. Global Humanized Antibody Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Research Institutes
  • Diagnostic Laboratories
  • Other End-Users
  • 6.5. Global Humanized Antibody Market, Sub-Segmentation Of Humanized Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monospecific Therapeutic Antibodies
  • Bispecific And Multispecific Antibodies
  • Antibody Drug Conjugates
  • Single Chain Variable Fragment Based Antibodies
  • Fragment Antigen Binding Based Antibodies
  • 6.6. Global Humanized Antibody Market, Sub-Segmentation Of Chimeric Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monospecific Therapeutic Antibodies
  • Bispecific And Multispecific Antibodies
  • Antibody Drug Conjugates
  • Single Chain Variable Fragment Based Antibodies
  • Fragment Antigen Binding Based Antibodies
  • 6.7. Global Humanized Antibody Market, Sub-Segmentation Of Fully Human Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monospecific Therapeutic Antibodies
  • Bispecific And Multispecific Antibodies
  • Antibody Drug Conjugates
  • Single Chain Variable Fragment Based Antibodies
  • Long Acting Half Life Extended Antibodies
  • 6.8. Global Humanized Antibody Market, Sub-Segmentation Of Murine Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monospecific Research Grade Antibodies
  • Hybridoma Derived Antibodies
  • Antibody Drug Conjugate Precursors
  • Single Chain Variable Fragment Based Antibodies
  • Fragment Antigen Binding Based Antibodies

7. Humanized Antibody Market Regional And Country Analysis

  • 7.1. Global Humanized Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Humanized Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Humanized Antibody Market

  • 8.1. Asia-Pacific Humanized Antibody Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Humanized Antibody Market

  • 9.1. China Humanized Antibody Market Overview
  • 9.2. China Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Humanized Antibody Market

  • 10.1. India Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Humanized Antibody Market

  • 11.1. Japan Humanized Antibody Market Overview
  • 11.2. Japan Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Humanized Antibody Market

  • 12.1. Australia Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Humanized Antibody Market

  • 13.1. Indonesia Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Humanized Antibody Market

  • 14.1. South Korea Humanized Antibody Market Overview
  • 14.2. South Korea Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Humanized Antibody Market

  • 15.1. Western Europe Humanized Antibody Market Overview
  • 15.2. Western Europe Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Humanized Antibody Market

  • 16.1. UK Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Humanized Antibody Market

  • 17.1. Germany Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Humanized Antibody Market

  • 18.1. France Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Humanized Antibody Market

  • 19.1. Italy Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Humanized Antibody Market

  • 20.1. Spain Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Humanized Antibody Market

  • 21.1. Eastern Europe Humanized Antibody Market Overview
  • 21.2. Eastern Europe Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Humanized Antibody Market

  • 22.1. Russia Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Humanized Antibody Market

  • 23.1. North America Humanized Antibody Market Overview
  • 23.2. North America Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Humanized Antibody Market

  • 24.1. USA Humanized Antibody Market Overview
  • 24.2. USA Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Humanized Antibody Market

  • 25.1. Canada Humanized Antibody Market Overview
  • 25.2. Canada Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Humanized Antibody Market

  • 26.1. South America Humanized Antibody Market Overview
  • 26.2. South America Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Humanized Antibody Market

  • 27.1. Brazil Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Humanized Antibody Market

  • 28.1. Middle East Humanized Antibody Market Overview
  • 28.2. Middle East Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Humanized Antibody Market

  • 29.1. Africa Humanized Antibody Market Overview
  • 29.2. Africa Humanized Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Humanized Antibody Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Humanized Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Humanized Antibody Market Competitive Landscape And Company Profiles

  • 30.1. Humanized Antibody Market Competitive Landscape
  • 30.2. Humanized Antibody Market Company Profiles
    • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Humanized Antibody Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Novartis AG
  • 31.3. AstraZeneca PLC
  • 31.4. Bristol-Myers Squibb Company
  • 31.5. GlaxoSmithKline plc
  • 31.6. Eli Lilly and Company
  • 31.7. Takeda Pharmaceutical Company Limited
  • 31.8. Amgen Inc.
  • 31.9. Biogen Inc.
  • 31.10. Daiichi Sankyo Company Limited
  • 31.11. UCB S.A.
  • 31.12. Genmab A/S
  • 31.13. Xencor Inc.
  • 31.14. Zymeworks Inc.
  • 31.15. MacroGenics Inc.

32. Global Humanized Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Humanized Antibody Market

34. Recent Developments In The Humanized Antibody Market

35. Humanized Antibody Market High Potential Countries, Segments and Strategies

  • 35.1 Humanized Antibody Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Humanized Antibody Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Humanized Antibody Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer